fluoxetine lilly

Company reports double-digit sales and earnings growth INDIANAPOLIS, July 24, 2008 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced financial results for the second quarter of 2008. Second-quarter results are presented on a reported basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all sales and expenses recognized by the company during the period. Year-to-date financial results are presented on both a reported and a pro forma basis. Pro forma results assume the ICOS acquisition was completed January 1, 2007. Pro forma results for the second quarter are not presented because the company completed the ICOS acquisition prior to second quarter of 2007. fluoxetine and neural fluoxetine level sibutramine fluoxetine fluoxetine fogginess confusion fluoxetine use and stomach problems fluoxetine dosage children

Fluoxetine help

Fluoxetine

Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat;
• clinical depression;
• obsessive-compulsive disorder in both adults and children where ritualised behaviour is endlessly repeated or thoughts recycle;
• bulimia nervosa — an eating disorder;
• panic disorder;
• premenstrual dysphoric disorder (PMDD) — a more severe form of PMS characterised by extreme mood swings, physical bloating and a tenderness of the breasts;
• hypochondria; and
• body dysmorphic disorder where people imagine themselves as disfigured.
Fluoxetine was launched in 1986 but remains in the top five most prescribed antidepressants in the USA. It increases the level of serotonin in the brain and helps to restore mood